Kezar Life Sciences (NASDAQ:KZR) announced that its board of directors has rejected an unsolicited takeover proposal from Concentra Biosciences, LLC. The offer was to purchase all outstanding shares of Kezar at $1.10 each, plus a contingent value right (CVR), which would entitle shareholders to 80% of future net proceeds from licensing or sales related to the company's development programs or intellectual property. The board determined that the proposal significantly undervalued Kezar, considering the company's cash balance of approximately $148 million as of September 30, 2024, while Concentra's bid amounted to a cash value of only $80 million.
In response to the takeover attempt and Concentra's rapid accumulation of a 9.9% stake in Kezar's common stock, the company has implemented a stockholder rights plan, effective immediately. This plan, which will expire on October 17, 2025, is designed to enable the board to engage with potential acquirers and is not intended to prevent an acquisition that is deemed beneficial for Kezar and its shareholders.
The rights issued under the plan will become exercisable in the event that an individual or group acquires a 10% stake (or 15% for passive institutional investors) in Kezar's common stock. Current shareholders exceeding these thresholds are grandfathered at their existing ownership levels but cannot increase their stakes without activating the rights plan.
The rights plan also includes typical flip-over and exchange features, allowing shareholders to maintain their proportional ownership in the event of further acquisition attempts. Kezar's board retains the option to redeem or exchange the rights before the plan's expiration date. Following these developments, H.C. Wainwright has maintained a Neutral rating on Kezar Life Sciences, without setting a specific price target.
Kezar Life Sciences rejected Concentra Biosciences' acquisition offer, deeming the proposal inadequate. The offer included a cash consideration of $1.10 per share and additional contingent value. In response, Kezar adopted a stockholder rights plan to prevent any entity from gaining control over the company without offering a fair control premium. The company's clinical trials have also seen significant developments. Kezar's PALIZADE Phase 2b clinical trial for lupus nephritis treatment was discontinued due to serious adverse events, but the PORTOLA Phase 2a trial for autoimmune hepatitis treatment remains on track, with results expected in 2025.
Financially, Kezar reported a second-quarter net loss of $22 million, with cash reserves of $164 million. Amid these developments, H.C. Wainwright maintained a Neutral rating on Kezar's shares, while TD Cowen and Jones Trading maintained their respective Buy and Hold ratings. These are recent developments impacting Kezar Life Sciences.
InvestingPro Insights
Recent InvestingPro data provides additional context to Kezar Life Sciences' (KZR) decision to reject Concentra Biosciences' takeover bid. As of the latest quarter, KZR's market capitalization stands at $59.54 million, significantly below the company's reported cash balance of $148 million. This discrepancy aligns with the board's assertion that the $1.10 per share offer undervalues the company.
InvestingPro Tips highlight that KZR "holds more cash than debt on its balance sheet" and "liquid assets exceed short term obligations," supporting the company's strong financial position. These factors likely contributed to the board's confidence in rejecting the takeover proposal.
However, investors should note that KZR is "quickly burning through cash" and "not profitable over the last twelve months," with a gross profit margin of -1040.71% in the last twelve months as of Q2 2024. These metrics underscore the challenges facing the company despite its substantial cash reserves.
Interestingly, KZR has shown a "strong return over the last month" and "strong return over the last three months," with price total returns of 41.57% and 26.91% respectively. This recent stock performance may reflect market optimism about the company's prospects or speculation surrounding potential acquisition interest.
For readers seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for KZR, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.